Since the emergence and spread of fluoroquinolone-resistant Neisseria gonorrhoeae, cephalosporins have been used as the primary treatment for gonococcal infections. In Japan, however, clinical isolates of N. gonorrhoeae have been found to be less susceptible to oral cephalosporins, including cefixime (1, 7, 11) . A mosaic penicillin-binding protein 2 (PBP 2) in clinical strains of N. gonorrhoeae, composed of fragments of PBP 2 from Neisseria cinerea and Neisseria perflava, has been reported to be associated with decreased susceptibility to oral cephalosporins (8) . We have suggested that the decreased affinity of mosaic-structure recombinant PBP 2 for oral cephalosporins might contribute to the decreased susceptibility of N. gonorrhoeae to these antibiotics (12) . In addition, recent studies have suggested that three amino acid substitutions in the mosaic PBP 2 might reduce the susceptibility of N. gonorrhoeae to cefixime (14) and that the penA mosaic structure, in conjunction with genetic polymorphisms in mtrR, porB1b, and ponA, might reduce the susceptibility to cefixime and ceftriaxone (9) . The emergence and spread of strains with such a mosaic PBP 2 could threaten the possibility of treating gonorrhea with cephalosporins. Therefore, the detection of the N. gonorrhoeae penA gene encoding the mosaic PBP 2 associated with decreased susceptibilities to oral cephalosporins could be useful for identifying cephalosporin resistance in clinical strains of N. gonorrhoeae. However, to the best of our knowledge, no studies of the detection of the mosaic penA gene have yet been reported. In the present study, we present our newly developed real-time PCR assay for the mosaic penA genespecific amplification and detection of N. gonorrhoeae associated with decreased susceptibilities to cephalosporins.
pAcHLT-A in TOP10 (Invitrogen, San Diego, CA) as previously reported (12) . Next, penA/pAcHLT-A was purified with a QIAprep Spin Miniprep kit (Qiagen, Hilden, Germany). The penA/pAcHLT-A was stored at Ϫ80°C; its copy number was calculated by measuring the optical density at 260 nm.
Detection of the mosaic structure of the N. gonorrhoeae penA gene. Specific amplification of the mosaic structure of the penA gene was performed by TaqMan PCR with the primers NG89-F2 (5Ј-GTTGGATGCCCGTACTGGG-3Ј), which was the same as a sequence region in N. cinerea, and NG89-R1 (5Ј-ACC GATTTTGTAAGGCAGGG-3Ј), which was the same as a sequence region in N. perflava. These were designed to specifically amplify the regions between nucleotides 801 and 1020 of the mosaic penA gene in N. gonorrhoeae and yielded a 220-bp fragment (Fig. 1) . The probe NG89-P1 (5Ј-6-carboxyfluorescein-CGGC AAAGTGGATGCAACCGA-3Ј-6-carboxytetramethylrhodamine) was designed to detect mutations between nucleotides 968 and 989 of the mosaic penA gene (Fig. 1) . The primers and probe were determined to be specific for the mosaic structure of the N. gonorrhoeae penA gene except in the Neisseria meningitidis penA gene (accession no. AY 294556) by online BLAST analysis on the National Center for Biotechnology Information website. The components of PCR in a final volume of 50 l included TaqMan 1000 Reaction PCR core reagents (Applied Biosystems Japan, Tokyo, Japan) containing AmpliTaq Gold, AmpErase uracil N-glycosylase, 10ϫ TaqMan Buffer A, deoxynucleoside triphosphate mix, and 25 mM MgCl 2 . The AmpliTaq Gold and AmpErase uracil N-glycosylase were added to final concentrations of 1.25 and 0.5 U/reaction, respectively. The primers, probe, and MgCl 2 were added to final concentrations of 1 M, 250 nM, and 5 mM, respectively. Finally, 5 l of template DNA was added to each reaction mixture. An ABI PRISM 7900 HT sequence detection system (Applied Biosystems Japan) was used for amplification and detection (2 min at 50°C, 10 min at 95°C, and 40 cycles of 15 s at 95°C and 60 s at 60°C).
Sequencing of the penA gene. The nucleotide sequence of the full-length penA genes from the N. gonorrhoeae clinical strains was determined as reported previously (8) . The penA genes were sequenced by the dye terminator method and with an automatic sequencer (model 3100; Applied Biosystems, Inc., Foster City, CA).
Statistical analysis. Mann-Whitney U tests were used to compare the MIC distributions. P values of less than 0.05 were considered significant.
RESULTS

Susceptibility to cephalosporins.
The cephalosporin susceptibilities of the 621 strains analyzed in the present study are summarized in Table 1 . There were no significant changes in the MIC distributions of cephalosporins for the clinical strains over 4 years.
Sensitivity. The 10-fold serially diluted plasmid DNA, penA/ pAcHLT-A, was amplified by real-time PCR, and the 220-bp fragment was identified by ethidium bromide staining when the sample contained more than 1 ϫ 10 1 copies/reaction. When the threshold cycles were plotted against the log 10 of the copy number of the penA/pAcHLT-A, linearity was observed over the range from 1 ϫ 10 1 to 1 ϫ 10 7 copies/reaction (Fig. 2) . In one out of three reactions, 1 ϫ 10 1 copies were detectable. Specificity. The specificity of the assay to detect the mosaic penA gene was determined by testing DNAs from N. gonorrhoeae (ATCC 19424 (Fig. 3) , with P values of less than 0.01. Two hundred forty-eight (96.9%) and 245 (95.7%) of the 256 strains with the mosaic PBP 2 exhibited cefozopran MICs in the range of 4 to 64 g/ml and cefdinir MICs in the range of 0.5 to 2 g/ml, respectively, over the 4 years. Two hundred thirty-three (91.0%) of the 256 strains with the mosaic PBP 2 exhibited cefixime MICs in the range of 0.25 to 2 g/ml. One hundred sixty-six (64.8%) exhibited cefixime MICs of 0.5 g/ml or greater than 0.5 g/ml. The distributions of ceftriaxone MICs for the strains with the mosaic PBP 2 and those without the mosaic PBP 2 overlapped. However, the ceftriaxone MICs for strains with the mosaic PBP 2, ranging from 0.004 to 2 g/ml, were significantly greater than those for strains without the mosaic PBP 2, which ranged from Ͻ0.001 to 0.5 g/ml.
Sequencing of the penA gene. There were nine strains of N. gonorrhoeae detected by the real-time PCR assay that showed susceptibility to cephalosporins (cefozopran, MICs of Ͻ0.5 g/ml; cefdinir, cefixime, or ceftriaxone, MICs of Ͻ0.25 g/ ml). Of these nine clinical strains, eight strains showed the mosaic structure and one strain showed a nonmosaic structure (Table 2 ). Compared to PBP 2 from GU01-12, this strain had an alteration of Asn-5423His. On the other hand, there were 12 strains of N. gonorrhoeae without the mosaic PBP 2 that showed decreased susceptibility to cephalosporins (cefozopran, MICs of Ն1 g/ml; cefdinir, cefixime, or ceftriaxone, MICs of Ն0.5 g/ml). In these clinical strains, the penA gene did not show the mosaic structure ( Table 2) .
DISCUSSION
We developed a real-time PCR assay for the detection of the mosaic structure of the N. gonorrhoeae penA gene, associated with decreased susceptibilities to cephalosporins. The realtime PCR assay targeting the mosaic structure of the N. gonorrhoeae penA gene was both highly specific and highly sensitive and could detect the mosaic PBP 2 in 256 of 621 clinical strains. A large number of clinical strains of N. gonorrheae could be examined for the presence of the mosaic PBP 2 without labor-intensive and time-consuming procedures, including sequencing of DNAs.
In our previous study, we sequenced the penA gene in 70 clinical strains of N. gonorrhoeae, finding this type of mosaic PBP 2 in 47 strains (8) . In this previous study, all of the strains with the mosaic PBP 2 exhibited cefdinir MICs in the range of 0.25 to 2 g/ml, while the remaining 23 strains, all possessing PBP 2 with Asp-345a or Asp-345a and additional amino acid alterations of one to six substitutions, showed cefdinir MICs in the range of 0.015 to 0.125 g/ml. With respect to cefixime, 45 of 47 strains with the mosaic PBP 2 showed MICs in the range of 0.25 to 1 g/ml and two showed MICs of 0.125 g/ml. The remaining 23 strains with nonmosaic PBP 2 showed cefixime MICs in the range of 0.015 to 0.125 g/ml. The clinical strains were distinctly categorized into oral-cephalosporin-resistant and -susceptible types based on the presence or absence of mosaic PBP 2. In the present study, we examined 621 clinical strains for the presence of the mosaic PBP 2 by means of our developed assay. The MICs of cephalosporins for 256 strains with the mosaic PBP 2 detected by the assay were statistically higher than those for strains without the mosaic PBP 2. This assay could thus be a relevant tool for detecting the mosaic PBP 2 associated with decreased susceptibility to cephalosporins.
In this study, 64.8% of clinical strains with mosaic PBP 2 exhibited cefixime MICs of 0.5 g/ml or greater. We also reported that the emergence and spread of N. gonorrhoeae with the mosaic PBP 2 showing decreased susceptibility to cefixime could be a threat to the cefixime treatment for gonorrhea. In particular, therefore, this assay, which is able to detect the mosaic PBP 2 in N. gonorrhoeae, could be useful in screening for resistance to cefixime in clinical strains of N. gonorrhoeae.
With respect to ceftriaxone, in both our previous and present studies, the ceftriaxone MICs for strains with mosaic PBP 2 were significantly greater than those for strains with nonmosaic PBP 2. However, the distribution of the former MICs overlapped that of the latter MICs, and some strains with mosaic PBP 2 showed lower ceftriaxone MICs than did those with nonmosaic PBP 2. Recent studies suggest that the ceftriaxone-resistant type is not based on the presence of mosaic PBP 2 (15, 16) . We also measured the affinity of mosaicstructure and non-mosaic-structure recombinant PBP 2 for cefdinir, cefixime, and ceftriaxone and found that the decreased affinity of mosaic-structure recombinant PBP 2 for oral cephalosporins might contribute to decreased susceptibility to these antibiotics in N. gonorrhoeae (12) . Furthermore, we showed that mosaic-structure recombinant PBP 2 showed the same affinity for ceftriaxone as non-mosaic-structure recombinant PBP 2, suggesting that the susceptibility of ceftriaxone may be determined not only by alterations in PBP 2 but also by other mechanisms. Therefore, the detection of the mosaic structure of the N. gonorrhoeae penA gene in clinical strains could not be effective enough to predict resistance to ceftriaxone. The present real-time PCR assay was significantly useful for detecting the mosaic PBP 2 in clinical strains of N. gonorrhoeae, which is indicative of decreased susceptibility to oral cephalosporins such as cefixime. However, this assay has several limitations. There were 12 strains of N. gonorrhoeae without the mosaic PBP 2 that showed decreased susceptibility to cephalosporins (cefozopran, MICs of Ն1 g/ml; cefdinir, cefixime, or ceftriaxone, MICs of Ն0.5 g/ml). In these clinical strains, the penA gene did not show the mosaic structure (Table 2), and susceptibility to cephalosporins appeared to be determined by other mechanisms (4) (5) (6) 13) . On the other hand, nine strains of N. gonorrhoeae were detected by the real-time PCR assay that showed susceptibility to cephalosporins (cefozopran, MICs of Ͻ0.5 g/ml; cefdinir, cefixime, or ceftriaxone, MICs of Ͻ0.25 g/ml). All but one of these clinical strains had the mosaic-structure penA gene (Table 2 ). In these eight strains with the mosaic structure, the mosaic PBP 2 could not decrease susceptibility to cephalosporins. These nine strains, which include one strain for which the sequence pattern result was different from the real-time PCR, require further investigation. The decreased susceptibility to cephalosporins in these strains could not be screened by the assay. Another limitation 
